and observed that wild-type p53 rendered mouse astrocytes We observed previously that wild-type p53 rendered neoresistant to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), a binatal mouse astrocytes resistant to 1,3-bis(2-chloroethyl)-functional alkylator used clinically, in a gene dose-dependent 1-nitrosourea (BCNU) in a gene dose-dependent fashion.
fashion. Resistance to BCNU in astrocytes could not be This effect of p53 appeared to be unrelated to its cell cycle explained by differential cell cycle arrest nor p53-mediated regulation or apoptotic functions. Because in many cell apoptosis (33).
types O 6 -methylguanine-DNA methyltransferase (MGMT)-
In some cells, resistance to BCNU and other alkylating mediated DNA repair is an important mechanism of resistagents is mediated by O 6 -methylguanine-DNA methyltransance to nitrosoureas, we measured MGMT activity in ferase (MGMT) and depletion of MGMT activity by O 6 -wild-type, heterozygous and p53 knockout neonatal mouse benzylguanine (BG) reverses resistance (34-38). MGMT astrocytes. Wild-type p53 astrocytes had significantly repairs DNA damage by removing alkyl groups from the greater MGMT activity than either heterozygous or p53 O 6 position of guanine, a critical site of alkylation by the knockout astrocytes: MGMT activity was~5-fold greater nitrosoureas. Three recent studies have suggested that p53 in wild-type p53 astrocytes than in p53 knockout cells.
may regulate MGMT activity (17,19,22) and Russell et al. (39) However, despite successful depletion of MGMT activity described a correlation between p53 mutation and sensitivity to in wild-type astrocytes by O 6 -benzylguanine (BG), resistprocarbazine, another clinically useful alkylating agent. Hence, ance to BCNU persisted unchanged. Moreover, we excluded to further investigate the relationship between p53 gene status the possibility that continued resistance to BCNU at the and BCNU resistance in normal astrocytes, we measured concentrations used could be explained by a compensatory MGMT activity in wild-type (ϩ/ϩ), heterozygous (ϩ/-) and induction of MGMT triggered by exposure to either BCNU p53 knockout (-/-) mouse astrocytes. or BG. Although these studies support a role for p53
To determine the effect of p53 on MGMT activity, astrocytes regulation of MGMT in neonatal mouse astrocytes, BCNU were isolated from mice with distinct p53 genotypes and resistance in wild-type cells appears to be mediated by a MGMT levels measured. Cultures of ϩ/ϩ, ϩ/-and-/-astronon-MGMT mechanism. Nevertheless, regulation of DNA cytes were prepared from the cerebrums of newborn TSG-p53 repair by MGMT may be another mechanism by which mice (GenPharm International, Taconic, Germantown, NY; 40) alterations of the p53 gene promote tumor initiation or using a procedure adapted from McCarthy and de Vellis progression. (41) . Cerebral hemispheres were isolated from unanesthetized neonates, dissected free of meninges and blood vessels and a single cell suspension prepared by a combination of enzymatic The p53 protein protects against DNA damage by arresting (0.025% trypsin) and mechanical dissociation. All cultures cell cycle progression (1-4), allowing time for repair, and by were grown in Dulbecco's modified Eagle's medium containing triggering apoptosis (5-7), perhaps through induction of genes 10% heat-inactivated fetal bovine serum and 50 U/ml penicillin/ involved in the oxidative stress response (8). In addition, p53 streptomycin. p53 genotype was determined by PCR using may regulate DNA repair directly, regulate multidrug resistance genomic DNA isolated from mouse tails (42) . Cells of identical or regulate other drug resistance mechanisms (9-23). Since genotype were pooled from littermates (2-6 mice) for each p53 can be normal or mutated in human cancers, including independent experiment. MGMT activity was assayed by incubation of cell extracts For northern blot analysis, total RNA was isolated from cultured cells using TRIzol Reagent (Gibco BRL Life Technologies, Burlington, Ontario, Canada) following the manufacturer's instructions. Selection of mRNA was performed using the PolyATract mRNA Isolation System III (Promega Corp., Madison, WI). As described (45) , samples and molecular weight markers (0.24-9.5 kb; Gibco BRL Life Technologies) were electrophoresed at 50 mA for 3-4 h in 1.1% agarose gels containing formaldehyde; mRNA was transferred to Gene Screen Plus membranes (Dupont Canada, Mississauga, Ontario, Canada) in 10ϫ SSC buffer (1.5 M NaCl, 0.15 M sodium citrate, pH 7.0) by capillary action. To block non-specific binding, membranes were prehybridized in a VWR Scientific (Toronto, Ontario, Canada) Model 2710 hybridization oven at 42°C in a buffer containing 50% formamide, 10% dextran sulfate, 1% SDS, 1 M NaCl and 100 µg/ml herring sperm DNA. After 1-4 h, radiolabeled probe (10 6 c.p.m./ml) was added to the prehybridization solution and incubated with constant rotation for 16-20 h at 42°C. 5Ј-Labeling of the at room temperature. For the random primed GAPDH probe, a more stringent protocol was used. These blots were washed twice for 5 min in 2ϫ SSC at room temperature, twice for 30 performed on 6-8-week-old mice, whereas we measured MGMT activity in astrocyte cultures isolated from newborn min in 2ϫ SSC, 1.0% SDS at 60°C and twice for 30 min in 0.1ϫ SSC, 0.1% SDS at room temperature. Membranes were mice. At early stages of differentiation, p53 expression is higher in rodent tissues, including the brain (48,49). The p53-exposed to a Storage Phosphor Screen (Molecular Dynamics, Sunnyvale, CA), screens scanned by a Personal Densitometer dependent MGMT activity observed in our studies might have been difficult to detect in adult animals, where p53 expression SI Model 375A (Molecular Dynamics) and images quantitated using ImageQuant software (Molecular Dynamics). All images is known to be low (48,49). In addition, p53-dependent MGMT activity may have been detected more readily in vitro because were below saturation and corrected for background.
p53 enhanced MGMT activity in a gene dose-dependent cell culture likely selects for less differentiated astrocytes with high p53 expression. manner. Homozygous ϩ/ϩ p53 astrocytes displayed significantly greater MGMT activity than ϩ/-astrocytes, which in Since BCNU-resistant ϩ/ϩ astrocytes (33) had high levels of MGMT activity, cells were pretreated with BG to determine turn exhibited significantly greater MGMT activity than -/-p53 astrocytes (Figure 1, left) . At the level of detection whether depletion of MGMT would sensitize ϩ/ϩ astrocytes to BCNU. First, to ensure that BG depleted MGMT, ϩ/ϩ afforded by the MGMT activity assay used in this study, -/-p53 astrocytes displayed MGMT levels only slightly above and -/-astrocytes were treated with either 25 or 50 µM BG for 2 h, after which MGMT activity was measured. BG stock those exhibited by MGMT-negative cells. The effect of p53 on MGMT mRNA expression was also examined. Astrocyte solution (100 mM) was made in filter-sterilized dimethylsulfoxide, stored at -80°C and diluted to 1 mM in phosphatecultures were prepared, mRNA isolated and northern blot analyses performed twice. In keeping with the activity assay buffered saline (PBS) when used; further dilutions were made with culture medium. BG significantly depleted MGMT activity results, ϩ/ϩ cells displayed higher levels of MGMT mRNA than -/-cells (see Figure 3) . in ϩ/ϩ p53 astrocytes (Ͼ90% reduction; Figure 1 , right). Although BG appeared to slightly deplete the already low basal In contrast to this result, Rafferty et al. (19) observed that basal levels of MGMT in whole mouse brain extracts were levels of -/-astrocytes, this difference was not statistically significant. MGMT levels found in BG-treated ϩ/ϩ astrocytes unaffected by p53 status. Moreover, Rafferty et al. (19) found lower levels of MGMT in brain extracts than detected by and the basal MGMT levels in -/-astrocytes were not significantly different (Figure 1 ). us in primary cultures of mouse astrocytes. Methodological differences may reconcile these apparently discordant results.
Next, ϩ/ϩ, ϩ/-and -/-astrocyte cultures were pretreated with 25 µM BG for 2 h, exposed to increasing concentrations For example, the experiments by Rafferty et al. (19) were Fig. 3 . Effect of BCNU and BG treatment on MGMT mRNA expression in wild-type p53 (A) and knockout (B) mouse astrocytes. Cells were exposed to either 40 µg/ml BCNU or 25 µM BG for 2 h. The first treated sample (t ϭ 0) was harvested after incubation and subsequent samples at the times specified (h). Quantified signal intensities for MGMT were normalized to GAPDH. MGMT mRNA expression remained constant with both treatments Fig. 2 . Effect of BG treatment on the resistance of wild-type mouse in both cell types. Since the wild-type and knockout samples were astrocytes to BCNU. Cells were pretreated with 25 µM BG for 2 h and hybridized together and exposed to the same storage phosphor screen, the exposed to increasing concentrations of BCNU. BG did not significantly relative mRNA expression levels of the control samples (i.e. wild-type reverse resistance to BCNU. The response of knockout astrocytes to BCNU versus knockout) are also demonstrated by this figure. CONT, control; is shown for comparison. Symbols represent the means of at least two GAPDH, glyceraldehyde 3-phosphate dehydrogenase. independent experiments, each performed in triplicate. Circles represent wild-type astrocytes treated with BCNU alone; squares, 25 µM BG pretreatment; triangles, knockout cells treated with BCNU alone. Bars depict the standard errors of the means.
of BCNU and cell viability tested using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay as described previously (33). BCNU was dissolved in absolute alcohol, diluted to 3.3 mg/ml with sterile water and stored at Ϫ80°C; subsequent dilutions were made with culture medium. Cytotoxicity was measured using the MTT assay as modified for chemosensitivity testing by Cole (50). (Colony formation could not be used to evaluate chemosensitivity in these nontransformed cells.) Briefly, 96-well plates were seeded and incubated at 37°C. To ensure equal cell numbers at 48 h, wild- type and heterozygous cells were seeded at 7.5ϫ10 3 /well and mouse astrocytes. Cells were treated with 40 µg/ml BCNU for 2 h. MGMT knockout p53 cells at 5ϫ10 3 /well. Cultures were treated with activity was measured at the time points specified (h). There was no BCNU for 2 h and then incubated for 96 h. At that time, significant change in activity in response to treatment. Bars depict the 100 µl of medium was removed, 25 µl MTT solution (2 mg/ml means of at least four replicates from a minimum of two independent experiments (Ϯ SEM). CONT, control.
in PBS) added and cultures incubated for 2 h at 37°C. To solubilize formazan crystals, 0.04 M hydrochloric acid in isopropanol was added to each well and mixed thoroughly.
BCNU or 25 µM BG for 2 h and samples taken at defined times for northern blot analysis and activity measurements. We Plates were kept at 37°C for 1 h and cell viability quantified by light absorbance (570 nm) in a Bio-Rad Model 3550 did not detect MGMT mRNA induction; expression remained constant in ϩ/ϩ and -/-astrocytes over 24 h (Figure 3 ). automated microplate reader (Bio-Rad Laboratories, Richmond, CA). To control for genotype-dependent growth Likewise, there was no significant change in MGMT activity over 48 h in ϩ/ϩ and -/-astrocytes in response to BCNU rates, dose-response curves were normalized expressing absorbance values relative to non-treated controls. Results (Figure 4 ). MGMT activity decreased at 12 and 24 h in ϩ/ϩ astrocytes, perhaps reflecting MGMT-mediated repair of BCNU were analyzed using the two-tailed t-test for independent means. Despite MGMT depletion, neither ϩ/ϩ astrocytes damage, but the change was modest and not statistically significant. The absence of MGMT induction in response to (Figure 2 ) nor ϩ/-cells nor knockouts were sensitized to BCNU by BG. Similarly, pretreatment of astrocytes with BCNU, while observed following exposure to other DNA damaging agents, may simply reflect the fact that induction is 50 µM BG did not increase sensitivity to BCNU significantly (data not shown).
an agent-specifc cellular response.
In conclusion, we examined MGMT activity in wild-type, Since MGMT induction has been reported in some tissues in response to DNA damage (19,51-56) and treatment with heterozygous and p53 knockout mouse astrocytes to further explore our previous observation that BCNU resistance in BG could conceivably lead to MGMT induction (either or both explaining the failure of BG to reverse BCNU resistance), neonatal mouse astrocytes is p53 dependent (33). p53 enhanced MGMT activity in a gene dose-dependent manner. However, ϩ/ϩ and -/-astrocytes were exposed to either 40 µg/ml apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74, despite successful depletion of MGMT activity in ϩ/ϩ astro- 
